Invention Grant
US07829534B2 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
有权
使用可溶性CTLA4突变体分子保护同种异体胰岛移植的方法
- Patent Title: Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
- Patent Title (中): 使用可溶性CTLA4突变体分子保护同种异体胰岛移植的方法
-
Application No.: US11978701Application Date: 2007-10-29
-
Publication No.: US07829534B2Publication Date: 2010-11-09
- Inventor: Christian P. Larsen , Thomas C. Pearson , Andrew B. Adams , Robert J. Peach , Peter S. Linsley , Joseph Roy Naemura , Jurgen Bajorath
- Applicant: Christian P. Larsen , Thomas C. Pearson , Andrew B. Adams , Robert J. Peach , Peter S. Linsley , Joseph Roy Naemura , Jurgen Bajorath
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Nickki L. Parlet
- Main IPC: A61K38/16
- IPC: A61K38/16 ; C07K14/705 ; C07K16/46
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
Public/Granted literature
- US20080160022A1 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules Public/Granted day:2008-07-03
Information query
IPC分类:
